summit clinical trial tirzepatide SUMMIT: Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity 408. Journal Club: The SUMMIT

This article is part of the PlexusDx Education Hub evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision

If approved, bimagrumab would likely be reserved for people at higher risk of losing too much muscle: Older adults , where muscle loss can lead to frailty, falls, or functional decline People with very low starting muscle mass , where further loss could affect mobility or metabolic health Those on long-term GLP-1 therapy , especially at higher doses or lower food intake That said, bimagrumab could also have a role in post-weight-loss maintenance

Here's what else to expect from the GLP-1 pills, including their efficacy and availability

Typical atrial flutter, the most common kind of atrial flutter, occurs in the right atrium

A finished preparation should be visually transparent and colourless with no suspended particulate